Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals.
نویسنده
چکیده
This monthly feature will help readers keep current on new drug, new indications, dosage forms and safety-related changes in labeling or use. Efforts have been made to assure the accuracy of this information; however, if there are any questions, please let us know at [email protected].
منابع مشابه
Cross-comparison of cancer drug approvals at three international regulatory agencies.
BACKGROUND The primary objective of the present study was to examine the drug approval process and the time to approval (tta) for cancer drugs by 3 major international regulatory bodies-Health Canada, the U.S. Food and Drug Administration (fda), and the European Medicines Agency (ema)-and to explore differences in the drug approval processes that might contribute to any disparities. METHODS T...
متن کاملAre there any differences in the regulations of personalized medicine among the USA, EU and Japan?
In their cautious review, Shah and Shah [1] emphasized differences in regulations of personalized medicine (PM) among the three major authorities, the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Specific points regarding the differences, however, were not raised for the drugs they selected for dis...
متن کاملRegulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
INTRODUCTION The efficacy of pharmaceuticals is most often demonstrated by randomised controlled trials (RCTs); however, in some cases, regulatory applications lack RCT evidence. OBJECTIVE To investigate the number and type of these approvals over the past 15 years by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). METHODS Drug approval data were downloade...
متن کاملIncreasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
1. Introduction 2. Economics of the pharmaceutical R&D process 2a. Costs and risks 2b. R&D returns 2c. The critical significance of patents in pharmaceuticals 3. The Orphan Drug Act of 1983 3a. Push and pull incentive programs 3b. Characteristics of the Orphan Drug Act 3c. Orphan drug designation and approvals 3d. Costs of orphan drugs 3e. Revenues from marketed orphan drugs 3f. Health benefits...
متن کاملMarketed therapeutic antibodies compendium
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as other countries, on a regular basis. As more mAbs become available to physicians and patients, keeping track of the number, types, production cell lines, antigenic targets, and dates and locations of approvals has become challenging. Data are presented here for 34 mAbs...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Hospital pharmacy
دوره 48 3 شماره
صفحات -
تاریخ انتشار 2013